Brought to you by 
Trius gets ex-Korean rights to Dong-A's oxazolidinones
12 Jun 2020
Executive Summary
Korean drug company Dong-A Pharmaceutical has licensed Trius Therapeutics (antibacterials) exclusive worldwide rights, excluding Korea, to develop, manufacture, and market a group of antibacterial compounds called oxazolidinones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Trius gets ex-Korean rights to Dong-A's oxazolidinones
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice